Skip Navigation

David E. Kozono, MD, PhD

Radiation Oncology

Make an Appointment


  • Senior Physician
  • Assistant Professor of Radiation Oncology, Harvard Medical School

Clinical Interests

  • Lung cancer
  • Stereotactic body radiation therapy
  • Thoracic malignancies

Diseases Treated

Contact Information

  • Appointments617-632-5734
  • Office Phone Number617-632-5734
  • Fax617-394-2667


David Kozono, MD, PhD, is a board certified radiation oncologist who specializes in the treatment of thoracic malignancies including lung cancer. His career goal is to improve treatment for patients with these cancers through basic, translational and clinical investigation. He graduated in 2005 from the Johns Hopkins University School of Medicine with an MD and a PhD in Biochemistry, Cellular and Molecular Biology, which he obtained studying under Nobel Laureate Dr. Peter Agre. In 2006, he completed an internship in internal medicine at Brigham and Women’s Hospital, and in 2010, he graduated from the Harvard Radiation Oncology Program. Upon graduation, he joined the Department of Radiation Oncology at the Dana-Farber/Brigham and Women’s Cancer Center, where he is a full-time clinician and researcher.


  • Harvard Radiation Oncology Program

Medical School:

  • Johns Hopkins University School of Medicine

Recent Awards:

  • Arnold Dunne Medical Intern Award
  • AACR-Aflac Travel Award
  • Melissa Lumberg Zagon Founder's Research Award


Basic/Laboratory: One of my top priorities is to identify and characterize lung cancer radiosensitizers. Standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) and small cell lung cancer (SCLC) involves concurrent radiotherapy (RT) and chemotherapy. Unfortunately, survival despite treatment is limited, in part due to an inability to administer enough radiation to eradicate the tumor without damaging surrounding vital organs. To discover novel therapeutics with the potential to act as radiosensitizers, we have been performing whole genome RNA interference and CRISPR/Cas9 screens in NSCLC lines. Once we identify promising gene targets, we test potential inhibitors in vitro and in vivo and characterize their mechanisms of action, e.g., impact on radiation-induced DNA damage repair, to elucidate biomarkers that may predict treatment responses.


Clinical/Translational: I am an Executive Officer for Alliance Foundation Trials, a North American research organization that develops and conducts cancer clinical trials with the Alliance for Clinical Trials in Oncology, working closely with pharmaceutical partners. Ongoing studies include a Phase I/II trial of the PARP inhibitor veliparib in combination with chemoradiotherapy for Stage III NSCLC, and a Phase II trial of the PD-L1 inhibitor atezolizumab as induction immunotherapy prior to chemoradiotherapy for Stage III NSCLC. I am also the Principal Investigator for the Brigham and Women’s Hospital Radiation Oncology All-Department Biorepository to Accelerate New Discoveries (BROADBAND) protocol for systematic collection of health information, treatment data, blood samples and other biospecimens for translational studies.


Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions